Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina
G Montalescot1, G Drobinski, J Maclouf
1Department of Cardiology, Hôpital Pitié-Salpétrière, Paris, France.
Insights
Patients with stable angina show increased thromboxane production during ischemia, but complement system activation is not observed. This suggests thromboxane, not complement, plays a role in angina-related myocardial ischemia.
Area of Science:
- Cardiology
- Biochemistry
- Immunology
Background:
- The complement system and arachidonic acid metabolites are implicated in myocardial ischemia.
- Experimental data suggests C5a may contribute to thromboxane production.
Purpose of the Study:
- To investigate C5a and thromboxane production during brief myocardial ischemia in stable angina patients.
- To determine the role of complement activation and platelet aggregation in ischemia-induced thromboxane release.
Main Methods:
- Assessed C5a and thromboxane B2 levels in coronary sinus blood during atrial pacing or percutaneous transluminal coronary angioplasty.
- Measured urinary thromboxane and prostacyclin metabolites before and after exercise testing.
- Monitored ST segment changes and lactate extraction to assess ischemia severity.
Main Results:
- Pacing-induced ischemia increased coronary sinus thromboxane B2 levels, correlating with lactate extraction changes.
- No significant increase in C5a, C3a, or C5b-9 was detected during ischemia.
- Patients with stable angina exhibited higher baseline urinary thromboxane metabolites, indicating chronic increased synthesis.
Conclusions:
- Thromboxane is acutely released during pacing-induced myocardial ischemia in stable angina, independent of significant platelet aggregation.
- Complement system activation does not appear to be involved in brief ischemic episodes in stable angina.
- Chronic elevation of thromboxane synthesis is present in patients with stable angina.
Background:
The complement system and arachidonic acid metabolites are involved in severe myocardial ischemia such as myocardial infarction. Furthermore, there is experimental evidence for C5a participation in thromboxane production.
Methods And Results:
We examined whether C5a and thromboxane are produced during brief and reversible episodes of myocardial ischemia induced in patients with stable angina. Twenty-five patients underwent either atrial pacing or percutaneous transluminal coronary angioplasty associated with arterial and coronary sinus blood sampling. Rapid atrial stimulation of patients with effort angina caused significant ST segment depression (delta ST = -1.7 +/- 0.2 mm), decreased fractional lactate extraction (from +12.8 +/- 2.5% baseline to -13.7 +/- 4.6% at peak ischemia, n = 13, p less than 0.001), and increased coronary sinus plasma thromboxane B2 levels (from 345 +/- 85 pg/ml baseline to 1,684 +/- 64 pg/ml at peak ischemia, p less than 0.01). Changes of fractional lactate extraction correlated significantly with changes of coronary sinus plasma levels of thromboxane B2. There was no change of coronary sinus 6-keto-PGF1 alpha levels. Similar pacing of control subjects (n = 6) did not cause release of lactate or thromboxane. Seventeen other patients underwent exercise testing with noninvasive measurements of thromboxane and prostacyclin metabolites in urinary samples collected before and after the test. No detectable increase of urinary 11-dehydrothromboxane B2 was measured in patients with stable angina after exercise-induced myocardial ischemia. However, basal 11-dehydrothromboxane B2 levels were significantly higher in patients with angina (105 +/- 25 pg/mmol creatinine, n = 9) than in control patients (45 +/- 8 pg/mmol creatinine, n = 8, p less than 0.05 between groups). Coronary sinus plasma levels of the anaphylatoxin C5a always remained below 4 ng/ml in patients undergoing pacing. More severe myocardial ischemia after coronary angioplasty (percent lactate extraction decreased from +24.8 +/- 2.7% baseline to -41.6 +/- 22.4% at peak ischemia, p less than 0.05) was not associated with C3a or C5b-9 generation. In all patients, there was neither platelet sequestration nor platelet alpha-granule release (no changes of beta-thromboglobulin/platelet factor 4 levels) into the coronary sinus plasma.
Conclusions:
Patients with stable angina have chronically increased thromboxane synthesis as assessed by excretion of urinary metabolites. Thromboxane is acutely released into the coronary sinus during pacing-induced ischemia without significant intracoronary platelet aggregation. Complement does not appear to be activated in stable angina during brief and reversible episodes of myocardial ischemia and does not contribute to thromboxane production.
Related Concept Videos
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Acute Coronary Syndrome III: Diagnostic Studies
Angina I: Introduction
Angina III: Clinical Manifestations and Assessment
Angina IV: Management
Angina V: Nursing Management


